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Bi-allelic Pathogenic Variants in HS2ST1 Cause
a Syndrome Characterized by Developmental Delay
and Corpus Callosum, Skeletal, and Renal Abnormalities
Pauline E. Schneeberger,1,7 Leonie von Elsner,1,7 Emma L. Barker,2 Peter Meinecke,1 Iris Marquardt,3
Malik Alawi,4 Katharina Steindl,5 Pascal Joset,5 Anita Rauch,5 Petra J.G. Zwijnenburg,6
Marjan M. Weiss,6 Catherine L.R. Merry,2 and Kerstin Kutsche1,*SummaryHeparan sulfate belongs to the group of glycosaminoglycans (GAGs), highly sulfated linear polysaccharides. Heparan sulfate 2-O-sul-
fotransferase 1 (HS2ST1) is one of several specialized enzymes required for heparan sulfate synthesis and catalyzes the transfer of the
sulfate groups to the sugar moiety of heparan sulfate. We report bi-allelic pathogenic variants inHS2ST1 in four individuals from three
unrelated families. Affected individuals showed facial dysmorphism with coarse face, upslanted palpebral fissures, broad nasal tip, and
wide mouth, developmental delay and/or intellectual disability, corpus callosum agenesis or hypoplasia, flexion contractures, brachy-
dactyly of hands and feet with broad fingertips and toes, and uni- or bilateral renal agenesis in three individuals. HS2ST1 variants
cause a reduction in HS2ST1 mRNA and decreased or absent heparan sulfate 2-O-sulfotransferase 1 in two of three fibroblast cell lines
derived from affected individuals. The heparan sulfate synthesized by the individual 1 cell line lacks 2-O-sulfated domains but had an
increase in N- and 6-O-sulfated domains demonstrating functional impairment of the HS2ST1. As heparan sulfate modulates FGF-
mediated signaling, we found a significantly decreased activation of the MAP kinases ERK1/2 in FGF-2-stimulated cell lines of affected
individuals that could be restored by addition of heparin, a GAG similar to heparan sulfate. Focal adhesions in FGF-2-stimulated
fibroblasts of affected individuals concentrated at the cell periphery. Our data demonstrate that a heparan sulfate synthesis deficit
causes a recognizable syndrome and emphasize a role for 2-O-sulfated heparan sulfate in human neuronal, skeletal, and renal
development.Introduction
Heparan sulfate proteoglycans (HSPGs) are glycoproteins
composed of a core protein to which heparan sulfate
(HS), a highly sulfated linear polysaccharide (glycosamino-
glycan; GAG), is attached. HSPGs are either associated with
the plasma membrane or excreted into the extracellular
matrix.1,2 In vitro and in vivo studies have demonstrated
the important role of HSPGs in various signaling pathways
during development. In particular, HS binds to several
secreted signaling molecules, such as members of the
Wnt/wingless, Hedgehog, transforming growth factor-
beta, and fibroblast growth factor (FGF) families.2–4 These
signaling molecules typically require the presence of
HS for high-affinity interactions with tyrosine kinase
receptors, with structural modifications within the poly-
saccharide, e.g., 2-O-sulfation, of particular importance
for selective triggering of specific transduction pathways,
such as FGF-mediated signaling.5–7
The complex biosynthesis of HS takes place, and is
controlled, in the Golgi apparatus and requires the interde-
pendent activity of a family of specialized enzymes.1 One
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 2020 American Society of Human Genetics.for HS synthesis is heparan sulfate 2-O-sulfotransferase 1
(HS2ST1) that catalyzes the transfer of the sulfate group
from 3’-phosphoadenosine 5’-phosphosulfate (PAPS) to
the 2-OH position of two uronic acids, glucuronic acid
(GlcA) and iduronic acid (IdoA).8,9 As HS2ST1 preferen-
tially acts on IdoA over GlcA, IdoA residues are commonly
2-O-sulfated in HS. All HS species analyzed to date are sub-
stantially 2-O-sulfated and have sulfated domains rich in
2-O-, 6-O-, and N-sulfated residues. 2-O-sulfated GlcA units
are rarely present.10,11 In most vertebrate genomes, only
one gene encoding an HS2ST isoform exists. The enzymes
share a high sequence homology across species, with 75%
similarity of human HS2ST1 to insect and 67% to Caeno-
rhabditis elegans Hs2st1, suggesting a crucial physiological
role in these organisms.12,13 While Drosophila Hs2st
mutants survive to the adult stage without obvious
morphological defects,14 C. elegans Hs2st mutants display
defects in cell migration and nervous system development,
particularly axon patterning.15,16 A more severe pheno-
type was observed inmice homozygous for a gene trapmu-
tation in Hs2st1. Knockout mice are stillborn or die within
the first day of life. All mutant mice show bilateral renal
agenesis and eye and skeletal abnormalities.17 Together,20246 Hamburg, Germany; 2Nottingham Biodiscovery Institute, University
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Figure 1. Pedigree of Individuals with Bi-allelic Variants in HS2ST1
Age at last examination and identified variants in HS2ST1 in the four affected individuals andmembers of three families are given below
each pedigree. For individual 3, the gestational age at induced termination of pregnancy is given. d, days; wks, weeks; y, years.
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required for morphogenesis during vertebrate develop-
ment.18
The molecular consequences of Hs2st1 deficiency on the
structural and functional properties of HS have been stud-
ied in primary mouse embryonic fibroblasts. In these cells,
the biosynthetic machinery produces a novel HS structure
lacking 2-O-sulfate groups but maintaining the overall
charge density with increases in N- and 6-O-sulfation.19
Compositional HS disaccharide profiling in Drosophila
Hs2st mutants has demonstrated a similar compensatory
mechanism suggesting that the retention of charge level
and distribution in HS may be responsible for the mild
phenotype of the Hs2st mutants, with 6-O-sulfate groups
replacing 2-O-sulfate groups during Drosophila develop-
ment.14 In contrast, the structurally altered HS generated
in Hs2st1 knockout mice is able to compensate for the
function of the wild-type chains inmany but not all tissues
during development.19
Here we report bi-allelic HS2ST1 variants in four
affected individuals from three unrelated families. The
core phenotype in these individuals, including one
severely affected fetus, comprises developmental delay
and/or intellectual disability in the three live individuals,
and corpus callosum agenesis or hypoplasia, facial dys-
morphism, short stature, and other skeletal abnormal-
ities. Uni- or bilateral renal agenesis was present in three
of the four affected individuals. For in vitro studies, we
used fibroblasts of three unrelated affected individuals
and found decreased or no HS2ST1 protein in two cell
lines, lack of 2-O-sulfated HS in individual 1 cells, low
FGF-2-induced activation of the MAP kinases ERK1/2
that can be restored by exogeneous addition of the GAG
heparin, and altered location of focal adhesions in fibro-
blasts from affected individuals. Our data suggest that
strongly diminished or absent HS 2-O-sulfotransferase 1
activity underlies the syndromic clinical presentation in
the four individuals reported here.2 The American Journal of Human Genetics 107, 1–18, December 3,Subjects and Methods
Study Approval
Informed consent for genetic analyses was obtained for all affected
individuals, and genetic studies were performed clinically or as
approved by the Institutional Review Boards of the relevant insti-
tutions. The parents of the affected individuals provided written
informed consent for participation in the study, clinical data
and specimen collection, genetic analysis, and publication of rele-
vant findings. Permission to publish photographs and radiographs
was provided for individuals shown in Figures 2 and 3.Whole-Exome Sequencing, Sequence Data Analysis, and
Variant Validation
Individual 1
Whole-exome sequencing (WES) was performed on genomic DNA
extracted from leukocytes of individual 1 and her healthy parents
by CeGaT. Enrichment was carried out using the SureSelect Hu-
man All Exon V6 kit (Agilent). Each captured library was loaded
and sequenced on the HiSeq platform (Illumina). Sequence reads
were aligned to the human reference assembly (UCSC hg19) using
the Burrows Wheeler Aligner (BWA mem, v.0.7.17-r1188).20
Variant discovery was performed with the Genome Analysis Tool-
kit (GATK, v.3.8),21 following the best practice recommendations
of the developers. Afterward, variants were functionally annotated
and compared to those documented in publicly accessible genetic
variant databases (e.g., dbSNP138, ClinVar, ExAC, and gnomAD)
using AnnoVar (v.2018-04-16).22 Only exonic and intronic vari-
ants that were private (absent in public database), rare (with a
minor allele frequency [MAF] of % 0.1% and no homozygotes in
public databases), or located at exon-intron boundaries ranging
from 10 to þ10 were retained. These variants should be absent
(de novo in individual 1) or present in the heterozygous state in
the healthy parents (homozygous or compound heterozygous in
individual 1). Exonic and splice variants were then prioritized by
pathogenicity assessment using multiple in silico tools (CADD,
REVEL, M-CAP, Human Splicing Finder 3.1, NetGene2-Server,
and Berkeley Drosophila Genome Project-Database).
Sequence validation and segregation analysis of theHS2ST1 var-
iants c.342delA (p.Val115*) and c.527T>C (p.Phe176Ser)2020
Figure 2. Photographs of Individuals
with Bi-allelic HS2ST1 Variants
(A and B) Face of individual 1 at age 3.5
years. Note prominent forehead with
bitemporal narrowing, thick eyebrows, hy-
pertelorism, upslanted and asymmetry of
palpebral fissures, bilateral epicanthus,
broad nasal root and tip, and wide mouth.
(C) Hands of individual 1 at age 5 years
showing brachydactyly with broad and
bulbous fingertips.
(D and E) Feet of individual 1 at age 5 years
with plantar malposition of 4th toes and
short toes with bulbous tips.
(F and G) Face of individual 2 at age 10
years. He had coarse face with upslanted
palpebral fissures, broad nasal tip, wide
mouth, full lips, deep philtrum, and small
teeth.
(H and I) Feet and left hand of individual 2
at age 12 years. Note broad thumb and
toes, bilateral pes planovalgus, and camp-
todactyly of 2nd to 5th toes on the right
and of the 5th toe on the left.
(J) Individual 3 (fetus) had flexion contrac-
tures of elbows and knees, supination of
both feet, and brachydactyly with broad
thumbs and halluces.
(K) Coarse facial appearance of individual
4 as newborn. He had short and upslanted
palpebral fissures, broad nasal root, bridge
and nasal tip, long and deep philtrum,
wide mouth, thin upper lip vermilion,
everted lower lip vermilion, pointed chin
with retrognathia, and full and sunken
cheeks.
(L and M) Hands and feet of individual 4
show brachydactyly with broad and
bulbous fingertips and toes.
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DNA from individual 1 and parents and also on fibroblast-derived
DNA and cDNA from individual 1 by Sanger sequencing. Primer
sequences are described in Table S1.
Individual 2
WES was performed on genomic DNA extracted from leukocytes
of individual 2 and his healthy parents. 2.5 mg of DNA was
sheared on a Covaris S2 instrument (Covaris). DNA libraries
were prepared using Kapa Biosystems reagents, and 1.0 mg of
the library was used for enrichment with Roche/NimbleGen
SeqCap EZ MedExome (Roche) according to the manufacturer’s
protocol. Sequencing was performed on an Illumina HiSeq
2500 platform (Illumina) with 125 bp paired-end reads. More
than 91% of the capture region was covered R 303 with a
mean bait coverage of approximately 1003 for each sample.
Variant calling was performed using an in-house analysis
pipeline. Alignment of sequence reads to the human genome
(hg19) was performed with the Burrows–Wheeler Aligner tool
(BWA-MEM v0.7.10) using default settings. Picard Tools
(v1.111) was used for sorting and marking duplicates. ForThe American Journal of Humanlocal realignment and base quality
score recalibration, we used the Genome
Analysis Toolkit (GATK; v.3.3-0), and for
variant calling, we used the GATK
HaplotypeCaller. Variants were filtertagged using the GATK VariantFiltration and annotated by
snpEff (v.4.0). Variant prioritization was performed using Carta-
genia Bench Lab NGS (Agilent Technologies). In short, a classi-
fication tree was used to select for variants present in individual
2 with MAF < 1% in control cohorts (dbSNP build 142), 1000
Genomes Phase 3 release v.5.20130502, and ESP6500 as well
as in-house controls. Prerequisite was that these variants had
been genotyped in at least 200 alleles. Subsequently, the re-
maining variants were further prioritized based on literature,
predicted (deleterious) effects on protein function by, e.g., trun-
cating the protein, affecting splicing, amino acid change, and
evolutionary conservation. The two identified HS2ST1 variants
were genotyped in DNA of individual 2’s healthy brother by
Sanger sequencing.
Individuals 3 and 4
Genomic DNA was extracted from amniotic fluid (individual 3),
cultivated fibroblast cells (individual 4), and EDTA blood sam-
ples from the parents. Trio WES in individual 3 and parents
was performed using the IDT Kit (v1.0) with paired-end
sequencing (NovaSeq 6000 S1 Reagent Kit (300 cycles), 150Genetics 107, 1–18, December 3, 2020 3
Figure 3. Radiographic Images of Individuals 1 and 2 with Bi-allelic HS2ST1 Variants
(A and B) Spine radiograph of individual 1 at age 2 years, 3 months. Anterior-posterior view showed thoracic scoliosis. Lateral view
revealed marked kyphosis of the thoracic spine with bi-convex, ‘‘barrel-shaped’’ vertebral bodies and narrowing of lumbar spinal
canal.
(C) Pelvis radiograph at age 2 years, 3 months: narrow iliac bones, subluxation of the left femoral head, coxa valga, andmaturation delay
of proximal femoral epiphyses.
(D) X-ray of left hand at age 3.5 years: bone maturation was markedly delayed with two carpals only and lack of radial epiphysis, bra-
chydactyly of all phalanges with particularly short and ovoidmiddle 2nd to 5th phalanges, lack of the 5thmiddle phalanx, and short 1st
proximal phalanx.
(E) X-ray of left foot at age 15 months: bone maturation was delayed, proximal phalanges were short and poorly modeled, and middle
phalanges showed reduced ossification.
(F and G) Spine radiographs of individual 2 at age 6 years demonstrate kyphosis of the thoracic spine and scoliosis of the lower lumbar
spine to the left due to hemivertebra L5.
(H and I) X-rays of feet at age 12 years show flexion contractures of 2nd to 5th toes.
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mina). Raw fastQ files were aligned to the hg19 reference
genome using the NextGENe software v.2.4.2.3 (SoftGenetics).
The average depth of coverage was 2853, and about 99.4%
of the targeted bases were covered by R 20 sequence reads.
Coding plus intronic (56 bp) variants observed in at least
16% of reads with sufficient quality level and with MAF % 2%
were investigated using the NextGENe Software (SoftGenetics)
for (1) de novo non-synonymous variants, (2) homozygous/
hemizygous non-synonymous variants, (3) compound het-
erozygous non-synonymous variants, and (4) synonymous
variants within 3 bp away from exon-intron-boundaries
potentially affecting splicing. Candidate variants were further
investigated for deleterious effects by various in silico
tools, the presence or absence in relevant genetic databases
(ClinVar, HGMD, gnomAD, CADD), by association of the
gene with the proband’s phenotype, by literature search
for evident functional information, and by GeneMatcher entry
for matching with unrelated, similarly affected subjects. The
HS2ST1 variant c.567A>C (p.Arg189Ser) was confirmed to be
present in individuals 3 and 4 in the homozygous state by
Sanger sequencing using an ABI Genetic Analyzer 3730 (Applied
Biosystems).4 The American Journal of Human Genetics 107, 1–18, December 3,Transcript Analysis
RNA isolation, complementary DNA (cDNA) synthesis, and
quantitative reverse transcription PCR (RT-qPCR) to determine
the relative HS2ST1 mRNA amount in fibroblasts of affected and
healthy individuals were performed as previously described.23
Qualitative RT-PCR to analyze HS2ST1 transcripts was performed
on fibroblast-derived cDNA according to standard PCR protocols
with the OneTaq Quick-Load 2X Master Mix (New England
Biolabs). PCR products were directly Sanger-sequenced. Primer
sequences are described in Table S1.
Antibodies
The following primary antibodies and dilutions were used: mouse
monoclonal anti-HS2ST1 (1:500; Santa Cruz Biotechnology; sc-
376530; clone G-10); rabbit polyclonal anti-p44/42 MAPK
(ERK1/2) (1:1,000; Cell Signaling Technology [CST]; #9102);
rabbit polyclonal anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/
Tyr204) (1:1,000; CST; #9101); and mouse monoclonal anti-paxil-
lin (IF: 1:100, WB: 1:1,000; BD Transduction Laboratories;
#612405; clone 349).
The following secondary antibodies and dilutions were used:
goat anti-mouse IgG:StarBright Blue 700 antibody (1:5,000 or
1:10,000; BioRad; #12004159); hFAB Rhodamine anti-GAPDH2020
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IgG (1:5,000; BioRad; #12004165); goat anti-mouse Alexa
Fluor 488-conjugated secondary antibody (1:1,000; Invitrogen;
#A11029).
Cell Culture
Primary fibroblasts obtained from a skin biopsy from individuals
1, 2, and 3 and four healthy individuals (control subjects) were
cultured in Dulbecco’s modified Eagle medium (DMEM; Thermo
Fisher Scientific) supplemented with 10% fetal bovine serum
(FBS; GE Healthcare) and penicillin-streptomycin (100 U/mL and
100 mg/mL, respectively; Thermo Fisher Scientific). Cells were
tested for mycoplasma contamination by PCR and confirmed to
be mycoplasma free.
Immunoblot Analysis
Cell lysates from affected individuals’ and control fibroblasts were
prepared, and immunoblotting was performed as previously
described.23 Briefly, cells were harvested in ice-cold RIPA buffer
and protein extracts were separated on SDS-PAGE and transferred
to polyvinylidene fluoride membranes. The membrane was incu-
bated with the indicated primary antibody at 4C overnight and
fluorescent dye-linked secondary antibodies at room temperature
for 1 h.
ERK Phosphorylation
Fibroblasts were seeded into 6-well plates (150,000 cells per well)
and incubated in starvation medium (0.1% FBS/DMEM) over-
night. The next day, cells were treated with 10 ng/mL recombinant
human FGF-2 (R&D Systems) in starvation medium for either
10min or 20min or left untreated. For the rescue experiment, cells
were treated with 10 ng/mL FGF-2 and 30 ng/mL heparin sodium
salt from porcine intestinal mucosa (Sigma-Aldrich), and for
control purposes cells were solely treated with 30 ng/mL heparin
sodium salt. Subsequently, plates were transferred on ice and
rinsed with ice-cold PBS. Cells were harvested in ice-cold RIPA
buffer supplemented with Mini Protease Inhibitor and PhosSTOP
(Roche), and lysates were subjected to SDS-PAGE and immunoblot
analysis. For quantification, pERK1/2 was normalized to total
ERK1/2, and the ratio at 0 min was set to 1.
Disaccharide Analysis
Cultured primary fibroblasts from individual 1 and two healthy in-
dividuals were seeded in T75 flasks. After 3–4 days, cells were
washed with PBS, then lysed using 1% (vol/vol) Triton
X-100/PBS for 30 min at room temperature while shaking.
Conditioned-media and cell extract samples were treated with
100 mg/mL Pronase (Roche Diagnostics) for 4 h at 37C. Cell
extracts were incubated for 15 min at 90C to deactivate the Pro-
nase, before treating with 14 mg/mL DNase I (Sigma-Aldrich)
and 10 mMMgCl2 overnight at 37
C to prevent DNA interference
with downstream processing. All preparations were loaded onto
1 mL diethylaminoethyl (DEAE)-Sephacel columns (Sigma-
Aldrich) and washed with 50 mL of 0.25 M NaCl, 20 mM
NaH2PO4.H2O (pH 7.0) to remove hyaluronan. The sulfated
GAGs were eluted with 5 mL of 1.5 M NaCl, 20 mM
NaH2PO4.H2O (pH 7.0) and desalted using PD-10 Sephadex
G-25M pre-packed columns (GE Healthcare). Purified GAGs were
freeze-dried, then digested using 0.8 mIU of each heparinase I,
II, and III (from Flavobacterium heparinum, Iduron) in 100 mL of
0.1 M sodium acetate and 0.1 mM calcium acetate (pH 7.0) forThe Am12 h at room temperature. The resulting disaccharides were
freeze-dried, then re-suspended in 10 mL of 0.1 M 2-aminoacri-
done (AMAC) and incubated at room temperature for 20 min. To
each reaction, 10 mL of 1M NaBH3CN was added, and incubation
continued at room temperature overnight in the dark. The AMAC-
labeled samples were separated by RP-HPLC in duplicate using a
Zorbax Eclipse XDB-C18 RP-HPLC column (35 mM, 2.1 mm 3
150 mm; Agilent Technologies), as described previously.24,25 Di-
saccharides were detected by fluorescence and were identified
and quantified in comparison with known amounts of commer-
cial disaccharide standards (Iduron). As described previously, due
to the efficiency of AMAC labeling varying according to specific
disaccharides, the raw peaks were multiplied by predetermined
correction factors.24Immunocytochemistry
50,000 cells per well were seeded on coverslips in 12-well plates
and incubated in starvation medium (0.1% FBS/DMEM) over-
night. The next day, cells were incubated with 10 ng/mL
FGF-2 in starvation medium for 1 h. Subsequently, cells were
rinsed with PBS, fixed with 4% paraformaldehyde (Morphisto)
in PBS, and washed three times with PBS. After treatment with
permeabilization/blocking solution (2% BSA, 3% goat serum,
0.5% Nonidet P40 in PBS), cells were incubated in antibody
solution (3% goat serum and 0.1% Nonidet P40 in PBS) contain-
ing mouse anti-paxillin primary antibody. Cells were washed
with PBS and incubated with Alexa Fluor 488-conjugated anti-
mouse secondary antibody in antibody solution. After extensive
washing with PBS, cells were embedded in ProLong Diamond
Antifade Mountant with DAPI (Invitrogen) on microscopic
slides. Cells were imaged with a widefield Zeiss fluorescence mi-
croscope system (Zeiss Axiovert 200M) equipped with a 633 oil
immersion objective lens and an Apotome unit. Images of repre-
sentative cells were taken to visualize and quantify the observed
morphological changes.Classification, Number, and Length of Focal Adhesions
Analysis of microscopic images was performed manually by use of
the ImageJ software tools (v.1.51j8; National Institutes of Health).
To examine the effect of HS2ST1 variants on location of paxillin-
containing focal adhesions (FAs), we classified FAs as ‘‘inner’’ and
‘‘outer’’ FAs based on the classification scheme reported in Legerstee
et al.26 FAs were classified as outer when they were in contact with
or located close to the cell membrane. FAs were classified as inner
when they were located further inward, with another FA located
in between them and the cell membrane. To compare the location
of FAs between different fibroblast cell lines, the ratio of inner to
outer FAs was determined. The total number of FAs per cell was
calculated as the sum of the number of inner and outer FAs. The
length of paxillin-positive signals in micrometers was determined
by use of the ImageJ tool for measuring distances, and the average
length of FAs per cell was calculated. Quantification of inner and
outer FAs, the total number of FAs, and FA length was performed
in at least six fibroblasts per cell line and experiment (control 1
[experiment #1: 6 cells; experiment #2: 9 cells; experiment #3: 7
cells], control 2 [8; 7; 7], individual 1 [6; 10; 8], individual 2 [6;
10; 7], individual 3 [7; 6; 8]) and a minimum of 21 cells in total
per cell line from three independent experiments. The number of
analyzed FAs from [number of cells] were for control 1 cell line
1,387 [22], control 2 1,627 [24], individual 1 1,108 [24], individual
2 1,128 [23], and individual 3 1,009 [21].erican Journal of Human Genetics 107, 1–18, December 3, 2020 5
Table 1. Clinical Features of Individuals with Bi-allelic HS2ST1 Variants














Exon(s) 2 and 4 1 and 4 4 4
Ethnicity white white white white
Consanguinity no no no no
Sex female male female male
Pregnancy and Birth
Perinatal complications none none oligohydramnios none
Gestational age (weeks) 37 þ 3 (Cesarean section) 38 pregnancy termination at
gestational week 23 þ 2
38 þ 2 (Cesarean section)
APGAR 10/10 8/9/10 N/A 6/8/10
Birth weight (z-score) 2,345 g (1.5 z) 3,080 g (0.5 z) N/D 3,020 g (0.8 z)
Birth length (z-score) 46 cm (1.5 z) 50 cm (0.5 z) N/D 47 cm (1.9 z)
OFC birth (z-score) 34 cm (0.1 z) N/D N/D 34 cm (0.7 z)
Last Examination
Age 5 y 14 y N/A 5 d
Weight (z-score) 10.8 kg (3.4 z) 66.4 kg at age 13 y (þ1.5 z) N/A 3.0 kg at age 15 d (0.9 z)
Height/length (z-score) 101 cm (2.2 z) 160 cm at age 13 y (þ0.1 z) N/A 47 cm at age 15 d (2.0 z)




severe mild to moderate N/A N/A
Muscular hypotonia no, muscle tone increased mild N/A severe
Motor development delayed delayed N/A N/A




Seizures no no N/A no
MRI scan hypoplasia of corpus
callosum
delayed myelination N/D agenesis of corpus callosum
Skeletal Features
Body disproportionate short
stature with short arms
pectus excavatum N/D long trunk
Limbs flexion contractures of elbow,
hip, and knee joints
genu valgum arthrogryposis with flexion
contractures of elbows




knees, and hips; shortening
of the upper arms with
exceeding skin folds
Hands and feet short hands and feet with
brachydactyly and broad
fingertips and toes; bilateral
pes adductus




camptodactyly of toes II-V
on the right and of toe V
on the left
supination of both feet;
brachydactyly; bilateral
pes adductus; broad distal
phalanges of fingers and
toes, especially of thumbs
and halluces
supination of both feet;
brachydactyly; bilateral
pes adductus; broad distal
phalanges of fingers and
toes, especially of thumbs
and halluces
(Continued on next page)
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Table 1. Continued
Individual # 1 (Family 1) 2 (Family 2) 3 (Fetus) (Family 3) 4 (Family 3)
X-ray findings spine: thoracic kyphoscoliosis;
barrel-shaped vertebral bodies;
narrow spinal canal.
pelvis: narrow iliac bones;
sub-luxation of left hip
joint; small femoral epiphyses;
coxa valga.
hands: bone age markedly
delayed; brachydactyly of
all phalanges; the middle
phalanges II-IV and proximal
phalanx of the thumb short
and ovoid; middle phalanx
V missing.




spine: kyphosis of the thoracic
spine; scoliosis of the lower
lumbar spine to the left due
to hemivertebra L5.


















normal N/A otoacoustic emissions
not present
Vision visual impairment mild myopia N/A posterior embryotoxon;
hypoplasia of the iris;
anterior polar cataract















nasal tip; wide mouth;
full lips; deep philtrum
coarse face; wide-set eyes;
thin upper and lower lip
vermilion; low-set and
posteriorly rotated ears
coarse face; broad forehead;
bitemporal narrowing; high
frontal hairline; fair hair;
periorbital fullness; short and
upslanted palpebral fissures;
prominent infraorbital fold;
broad nasal root, bridge and
nasal tip; long and deep
philtrum; wide mouth;
macroglossia; thin upper lip
vermilion; everted lower lip
vermilion, pointed chin with
retrognathia; full and sunken
cheeks; short neck; low-set,
posteriorly rotated ears with
squared superior portion of
helices and prominent crus
of helices; attached earlobes
Teeth N/D small teeth N/A N/A
Additional findings dystrophy constipation; two
additional nipples
none capillary hemangiomas on
the left side of the face, on
the left butt cheek, and of
the popliteal fossa
Abbreviations: d, days; m, months; N/A, not applicable; N/D, no data; OFC, occipital-frontal circumference; y, years; z, z-score.
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Identification of Bi-allelic Variants in HS2ST1 in Three
Unrelated Affected Individuals with Developmental
Delay, Corpus Callosum Hypoplasia or Aplasia, and
Skeletal and Renal Abnormalities
We investigated family 1 with one affected girl (individual
1), first seen at age 3 years and 6 months (Figure 1 and
Table 1). She was born to a non-consanguineous coupleThe Amat 37þ 3 weeks of gestation by Cesarean section with mea-
surements in the lower normal range for length andweight
and mean occipito-frontal head circumference (OFC). Her
psychomotor development during infancy and early child-
hood was severely delayed. Brain MRI at age 3 years re-
vealed partial agenesis of the corpus callosum with absent
body and splenium and hypoplastic rostrum and genu.
Facial dysmorphism at the age of 3.5 years comprised
scaphocephaly, prominent forehead with bitemporalerican Journal of Human Genetics 107, 1–18, December 3, 2020 7
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palpebral fissures with a left narrow one, bilateral epican-
thus, broad nasal root and tip, wide mouth, and low-set,
dysmorphic ears (Figures 2A and 2B). On last examination
at age 5 years, her length was 101 cm (2.2 z), weight was
10.8 kg (3.4 z, according to length), and OFC was 46 cm
(3.4 z). Apart from dystrophy and disproportionate short
stature with short appearing limbs, she had kyphoscoliosis,
flexion contractures of elbow, hip, and knee joints, brachy-
dactyly of hands and feet, and broad fingertips and toes
(Figures 2C–2E). Muscle tone was increased, and her motor
and cognitive development severely delayed. She could
not speak. Her vision appeared to be impaired, though
ophthalmologic examination—including fundoscopy
and visually evoked potentials—revealed normal results.
Ear-nose-throat studies disclosed submucous cleft palate
andmucotympanum causing reduced conduction; in addi-
tion, a sensorineural component of hearing impairment
was diagnosed. Radiologic studies of the spine, pelvis,
hand, and foot at different ages revealed thoracic kypho-
scoliosis with anteriorly rounded (barrel-shaped) vertebral
bodies (Figures 3A and 3B), subluxation of the left hip
joint, bilateral small femoral epiphyses, and coxa valga
(Figure 3C). Hand X-ray demonstrated camptodactyly
and brachydactyly, markedly delayed bone maturation,
and short phalanges with particularly short and plump
(ovoid) middle phalanges (Figure 3D). Bone maturation
of the foot was also delayed, and the rudimentary middle
phalanges were almost unossified (Figure 3E). We per-
formed WES in individual 1 and her healthy parents and
identified the compound heterozygous variants
c.342delA, predicting the introduction of a premature
stop codon (p.Val115*), and c.527T>C, predicting the
amino acid substitution p.Phe176Ser, in HS2ST1 (Figures
1 and S1A and Table S2). Both variants are absent in public
databases including the gnomAD browser (Table S2). The
genetic variants were validated in individual’s 1 DNA using
Sanger sequencing. Her father was a heterozygous carrier
of the 1-bp deletion and her mother of the c.527T>C
change (Figures 1 and S1A).
Through GeneMatcher,27 we identified two unrelated
families with three affected individuals harboring bi-allelic
variants in HS2ST1 (Figure 1). Individual 2 (family 2), a
14-year-old boy, carried the compound heterozygous
variants c.59_62delinsGAA (p.Phe20*) and c.493G>T
(p.Asp165Tyr) (Figure 1 and Table S2). The c.59_
62delinsGAA variant is absent in public databases, and
the c.493G>T change is listed twice in the heterozygous
state in gnomAD (MAF: 0.0008695%; Table S2). The
c.59_62delinsGAA variant was inherited from the mother,
and the p.Asp165Tyr variant was paternally inherited. The
healthy older brother of individual 2 carried the HS2ST1
missense variant in the heterozygous state (Figure 1). Indi-
vidual 2 was born after an uneventful pregnancy at gesta-
tional age of 38 weeks with a birth weight of 3,080 g
(0.5 z) and length of 50 cm (0.5 z) (Table 1). Shortly af-
ter birth, clubfoot on the right and bilateral cryptorchi-8 The American Journal of Human Genetics 107, 1–18, December 3,dism was noted. Within the neonatal period he developed
an urosepsis, and unilateral kidney agenesis was identified.
He was first seen at the Clinical Genetics outpatient clinic
at the age of 3 months. He is the second child of non-
consanguineous parents. Family history did not reveal
any relevant conditions. Upon physical examination his
height, weight, and OFC were all normal. Radiologic
studies at the age of 6 years revealed kyphosis of the
thoracic spine and scoliosis of the lower lumbar spine
due to hemivertebra L5 (Figures 3F and 3G). X-rays of
feet demonstrated flexion contractures of the 2nd to 5th
toes (Figures 3H and 3I). Facial dysmorphism at the age
of 10 years comprised coarse face, upslanted palpebral fis-
sures, broad nasal tip, wide mouth with full lips, deep phil-
trum, and high palate (Figures 2F and 2G). He had broad
thumbs and toes and bilateral pes planovalgus (Figures
2H and 2I), prominent fingertip pads, and a small umbili-
cal hernia. Upon follow up, his development was delayed.
At the age of 14 years, he walked with a walker, spoke with
limited articulation, had a considerable vocabulary, and
was able to read. Metabolic screen of urine, plasma, and
cerebrospinal fluid did not show any abnormalities.
Furthermore, he had small teeth and detrusor underactiv-
ity (Table 1).
In the third family, the homozygous HS2ST1 missense
variant c.567A>C (p.Arg189Ser) (absent in gnomAD) was
identified in a fetus (individual 3) after induced abortion
at 23 þ 2 weeks of gestation (Figure 1 and Table S2). Both
healthy parents were heterozygous carriers of the HS2ST1
missense change (Figure 1). The female fetus was the first
child of non-consanguineous parents with unremarkable
family history (Table 1). Until gestational week 16, the
pregnancy was uneventful. Severe oligohydramnion was
detected at week 21, and bilateral kidney agenesis was sus-
pected. Autopsy showed a fetus who was too small for
gestational age with fixed flexion contractures of the el-
bows and hips, extension deformities of knees, and supina-
tion of both feet with bilateral pes adductus with broad
and medially deviated halluces. The hands appeared short,
and both thumbs were broad and short. Eyes appeared
wide-set, the upper and lower lip vermilion was thin, and
ears were low-set and posteriorly rotated (Figure 2J).
Further autoptic findings were a single umbilical artery,
bilateral kidney agenesis, a rudimentary bladder, and unlo-
bulated lungs (Table 1). Individual 4 was the younger
brother of individual 3 and also carried the HS2ST1
p.Arg189Ser variant in the homozygous state (Figure 1,
Tables 1 and S2). He was born at 38 þ 2 weeks of gestation
by Cesarean section. During pregnancy corpus callosum
agenesis and unilateral kidney agenesis were suspected by
ultrasound in week 21 of gestation and confirmed by fetal
MRI. At birth, his weight was 3,020 g (0.8 z), length was
47 cm (1.9 z), and OFC was 34 cm (0.7 z). His APGAR
scores were 6, 8, and 10 at 1, 5, and 10 min of life. He
was admitted to the neonatal intensive care unit for
15 days and received cardiorespiratory and feeding
support. He had a coarse facial appearance with broad2020
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upslanted palpebral fissures, periorbital fullness, promi-
nent infraorbital fold, broad nasal root, bridge, and tip,
full and sunken cheeks, long and deep philtrum, wide
mouth, macroglossia, thin upper vermilion with exagger-
ated cupid-bow, everted thick lower vermilion, pointed
chin, retrognathia, low-set, posteriorly rotated ears,
squared superior portion of helices, prominent crus of he-
lices, attached earlobes, and short neck (Figure 2K). He had
capillary hemangiomas on the left side of the face, extend-
ing from the temporal region to the supraorbital region,
left side of the nose and cheek, on the left butt cheek,
and the left popliteal fossa. Limbs showed arthrogryposis
with flexion contractures of elbows, knees, and hips. Supi-
nation of both feet, brachydactyly with broad fingertips
and toes, broad distal phalanges of finger and toes, espe-
cially of thumbs and halluces, bilateral pes adductus (Fig-
ures 2L and 2M), and apparently shortening of the arms
with exceeding skin folds were observed. Ophthalmologic
examination revealed a posterior embryotoxon, hypopla-
sia of the iris, and anterior polar cataract. Abdominal
ultrasound confirmed left kidney agenesis. Otoacoustic
emissions were not present, and weight gain was difficult
because of poor sucking (Table 1).
HS2ST1 is intolerant to functional genetic variation, as
only 69% of the expected missense (observed/expected
score: 0.69) and 20% of the expected loss-of-function
variants (observed/expected score: 0.2) were found in
gnomAD,28 further indicating a pathogenic role of
the HS2ST1 variants in the affected individuals. The
HS2ST1 missense variants p.Asp165Tyr, p.Phe176Ser, and
p.Arg189Ser were predicted to have a damaging impact
on protein function by three in silico tools and affect an
intolerant amino acid residue each (Table S2). Together,
based on rarity or absence of the identifiedHS2ST1 variants
in population databases, two likely truncating variants,
three missense variants with a possible damaging effect
on enzymatic activity, as well as overlapping clinical
features in the four affected individuals, we believe the
bi-allelic HS2ST1 variants to underlie the phenotype in
all of them. This is further underscored by renal, skeletal,
and eye abnormalities inHs2st1 knockout mice,17 showing
similarities with the clinical manifestations of the fetus
and the three live individuals described here.
Reduced HS2ST1 mRNA Levels and Decreased or Absent
HS2ST1 Protein in Fibroblast Cells of Two Affected
Individuals
To characterize the effect of compound heterozygous and
homozygous HS2ST1 variants on transcript and protein
level, we used fibroblasts derived from individuals 1, 2,
and 3. We first PCR-amplified fibroblast-derived cDNA
from the three individuals and Sanger-sequenced the
PCR products to identify possible aberrantHS2ST1mRNAs.
In individual 1, we found predominant abundance of
HS2ST1 transcripts with the c.527T>C variant suggesting
nonsense-mediated mRNA decay (NMD) of mRNAsThe Amharboring the c.342delA deletion (Figure S1A). In contrast,
in fibroblast-derived cDNA of individual 2, HS2ST1 tran-
scripts with the delins variant and the c.493G>T change
were detectable in equal amount suggesting no efficient
clearance of HS2ST1 mRNAs with the c.59_62delins
variant by NMD (Figure S1B). As expected, HS2ST1 cDNA
analysis in individual 3 revealed the presence of mRNAs
with the c.567A>C change (Figure S1C).
We next determined the relative levels of HS2ST1mRNA
in cells of affected individuals by RT-qPCR. HS2ST1 mRNA
amount was reduced to 53% and 64% in fibroblasts of
individuals 1 and 2, respectively, compared to control 1
cells (50% and61% compared to control 2 cells; Figures
4A and S2). This is in line with data from qualitative
HS2ST1 transcript analysis in cells of individual 1 and un-
derscores NMD of mRNAs harboring the premature stop
codon p.Val115* (Figure S1A). In contrast, reduced
HS2ST1 mRNA amount in individual 2 cells is possibly
due to a decay of both mutant mRNAs as the delins and
the c.493G>T variants were present in the RT-PCR ampli-
con sequences (Figure S1B). The level of HS2ST1 mRNA
in cells of affected individual 3 was comparable to that of
control cells (93% and 88% compared to control 1
and 2, respectively), suggesting stability of HS2ST1 tran-
scripts harboring the missense variant p.Arg189Ser
(Figure 4A).
We used whole-cell lysates from primary fibroblast cul-
tures for HS2ST1 protein analysis via immunoblotting.
HS2ST1 was almost completely absent in fibroblasts of
individual 2 (Figures 4B, 4C, and S3). The remaining pro-
tein was 7% in cells of individual 2 compared to cells of
controls 1 and 2 (Figure 4C). In cells of individual 1, the
HS2ST1 protein level correlated well with the determined
transcript amount: 49%–52% of HS2ST1 protein was
found in fibroblasts of individual 1 compared to control
1 and 2 cells (Figure 4C). All HS2ST1 mutant transcripts
in individual 3 cells seemed to give rise to protein as the
same amount of HS2ST1-Arg189Ser mutant protein was
detected in individual 3 cells compared to wild-type
HS2ST1 in control 1 cells (Figures 4B and 4C). Together,
the data suggest that both the C-terminally truncated
HS2ST1-Phe20* and the HS2ST1-Asp165Tyr mutant
proteins in individual 2 cells show intrinsic instability
and/or are subject to enhanced degradation, while
HS2ST1 protein with the amino acid change p.Phe176Ser
or p.Arg189Ser seems to be stable in fibroblast cells.
Together with data from structural and mutation analysis
of HS2ST112,13 (see above), the substitutions p.Phe176Ser
and p.Arg189Ser likely have a negative impact on HS2ST1’s
enzymatic activity rather than on protein stability.
Heparan Sulfate from Fibroblasts of Individual 1 Lacks
2-O-Sulfation and Shows an Increase in N- and 6-O-
Sulfation
HS is a highly sulfated linear polysaccharide that un-
dergoes a series of modifications during its biosynthesis.
These modifications transform a uniform N-acetylerican Journal of Human Genetics 107, 1–18, December 3, 2020 9
Figure 4. Determination of HS2ST1 mRNA and Protein Amount in Fibroblasts from Affected Individuals
(A) Quantification of HS2ST1 transcripts by RT-qPCR. RNA was obtained from fibroblasts of individuals 1, 2, and 3 and two healthy in-
dividuals (control). GAPDH mRNA was used as an internal control, and the amount of HS2ST1 mRNA relative to GAPDH mRNA is pre-
sented. HS2ST1 variants found in the three individuals are shown on the right. The mean of three independent experiments 5 SD is
given. Mean of technical duplicates from each experiment is shown in Figure S2.
(B) Immunoblot of lysates obtained from fibroblasts of three affected individuals and two control subjects. The amount of HS2ST1 pro-
tein was monitored with an anti-HS2ST1 antibody, and an anti-tubulin antibody was used for equal loading. Uncropped blots are shown
in Figure S3.
(C) Band intensities of fluorescence signals were quantified using the ChemiDoc imaging system. The mean of three independent
experiments 5 SD is given. One-way ANOVA with Bonferroni correction was used for statistical analysis: *p % 0.05; **p % 0.01; ***p
% 0.001; ****p % 0.0001; ns, not significant.
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complex mature HS chain with alternating high-sulfated
and low-sulfated domains. N-sulfation of specific glucos-
amine residues converts clusters of GlcNAc residues to
N-sulfated glucosamine (GlcNS)-rich regions. This is fol-
lowed by epimerization of selected glucuronic acid (GlcA)
residues to form iduronic acid (IdoA) and further O-sulfa-
tion including 2-O-sulfation (2S), primarily of IdoA resi-
dues (IdoA(2S)), 6-O-sulfation (6S), and rarely 3-O-sulfation
(3S) of GlcNS/GlcNAc.1 Structural analysis of embryonic
fibroblast HS of the Hs2st1 knockout mouse demonstrated
increased N- and 6-O-sulfation in the absence of any 2S. A
particular increase in uronic acid (UA)-GlcNS and UA-
GlcNS(6S) residues of the HS chains has been identi-
fied.19 To determine whether a similar shift in global sulfa-
tion patterning occurred in fibroblasts of individuals with10 The American Journal of Human Genetics 107, 1–18, December 3bi-allelic HS2ST1 variants, we carried out disaccharide
compositional analysis on HS isolated from fibroblasts
expanded in culture. We were able to isolate sufficient HS
from cell lysates and conditioned media of individual 1
and two controls to carry out compositional analysis, but
not from fibroblasts of individuals 2 and 3. Cell lysate
and conditioned media HS was analyzed separately and
compared against equivalent material isolated from con-
trol cells. In both cell lysate and conditioned media mate-
rial from individual 1, 2S was significantly reduced
compared to controls (Figures 5A–5D). Specifically, total
2S was 0.6% in individual 1 cell lysate compared to 15%
in both control cell lysates (Figure 5C). Similar differences
were observed in conditioned media (individual 1 condi-
tioned media 2%; control 1 11%; control 2 8%;
Figure 5D). The 2S trace level seen in conditioned media, 2020
Figure 5. Comparative Disaccharide Composition of Heparan Sulfate from Lysates and Conditioned Media of Fibroblasts of Individ-
ual 1 and Two Control Subjects
From the disaccharide analysis (cell lysate in A and conditionedmedia in B), the total levels ofN-sulfation (NS),N-acetylation (NAc), 2-O-
sulfation (2S), and 6-O-sulfation (6S) of isolated heparan sulfate chains could be calculated (cell lysate in C and conditioned media in D)
and are represented in the above charts. Results are an average of three (cell lysate andmedia from individual 1, cell lysate from controls 1
and 2) or two (media from controls 1 and 2) independent samples (mean 5 SD). Two-way ANOVA with Tukey correction was used for
statistical analysis: *p% 0.05; **p% 0.01; ***p% 0.001; ****p% 0.0001; GlcNAc, N-acetyl glucosamine; GlcNS, N-sulfated glucosamine;
ns, not significant; UA, uronic acid.
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serum (serum-containing media not exposed to cells was
found to have 6% 2S; Figure S4). Remarkably, we observed
a similar increase inN-sulfation (NS) and 6-O-sulfation (6S)
as seen in theHs2st1 knockout mouse with cell lysate of in-
dividual 1 HS having 19% 6S and 66% NS compared to
12% 6S in both controls and 45% and 40% NS in control
1 and 2, respectively (Figures 5A and 5C). A similar pattern
of altered sulfation was seen in HS isolated from the
conditioned media (Figures 5B and 5D), with increases in
UA-GlcNS(6S) and UA-GlcNS seen in both cell lysate
and conditioned media of individual 1 (Figures 5A and
5B). The data indicate a strongly diminished or nearly
absent 2-O-sulfotranserase activity in cells derived from in-
dividual 1 with the bi-allelic HS2ST1 variants p.Val115*
and p.Phe176Ser.
Reduced FGF-2-Induced Activation of the MAP Kinases
ERK1/2 and Restoration of the FGF-2 Stimulatory
Activity by Heparin Addition to Fibroblasts of Affected
Individuals
HS modulates FGF signaling by concomitantly interacting
with both the growth factor and the receptor to form aThe Ameternary complex.29,30 For optimal interaction between
the three molecules, 2-O-sulfation of HS is an essential
requirement.6,7 In line with this, the aberrant HS from
Hs2st1/ mice has a reduced affinity for FGF-1 and
FGF-2; however, embryonic fibroblasts from these mice
were still able to signal in response to these factors,
possibly as a result of the concomitant increase in N- and
6-O-sulfation.19 MAP kinase signaling, e. g. dual phosphor-
ylation of ERK1/2, is one well-studied pathway to assess
the dependence of HS for FGF binding and activation of
cell-surface FGF receptors.19,31,32 We next determined the
phosphorylation status of ERK1/2 in serum-starved fibro-
blasts that were treated with FGF-2 for 10 or 20 min. We
identified an increase over baseline in ERK1/2 phosphory-
lation after 10 and 20 min of FGF-2 stimulation for all cell
lines (Figures 6A and S5). However, the response to FGF-2
was significantly less in cells of affected individuals
(Figure 6A, compare upper with lower panel). ERK1/2
phosphorylation after 10 min of FGF-2 treatment was
1.5- to 1.7-fold lower in cells from individuals 1, 2, and 3
than in control 1 fibroblasts (and 1.4- to 1.5-fold lower
than in control 2 fibroblasts; Figure 6B). Similarly, after
20 min of FGF-2 treatment, the phosphorylation level ofrican Journal of Human Genetics 107, 1–18, December 3, 2020 11
Figure 6. Effect of FGF-2 and Heparin Treatment on ERK1/2 Activation in Fibroblasts from Affected Individuals
(A) Immunoblot of lysates obtained from fibroblasts of individuals 1, 2, and 3 and two controls. After serum starvation overnight, cells
were stimulatedwith 10 ng/mL FGF-2 (upper and lower panels) or 10 ng/mL FGF-2 and 30 ng/mL heparin (middle panel) for 0–20min as
indicated. Endogenous phosphorylated ERK1/2 (pERK1/2) and total ERK1/2 were detected in whole cell lysates by immunoblotting.
Representative blots are shown; uncropped blots are shown in Figure S5.
(B) Band intensities of fluorescence signals were quantified using the ChemiDoc imaging system. pERK1/2 was normalized to total ERK1/
2, and the ratio at 0minwas set to 1. Themean of three independent experiments5 SD is given. Two-way ANOVAwith Tukey correction
was used for statistical analysis: *p % 0.05; **p % 0.01; ***p % 0.001; ****p % 0.0001; ns, not significant.
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three cell lines derived from affected individuals compared
to control 1 and 2 cells (Figure 6B). Together, these data
demonstrate a significantly reduced FGF-2-dependent
MAPK signaling response in cell lines of the three affected
individuals pointing to a possible requirement of 2-O-
sulfated HS for normal FGF-2-induced signaling in these
cells.
To determine whether the diminished stimulatory ef-
fect of FGF-2 in fibroblasts of affected individuals can
be restored by exogeneous (commercially available)
heparin, a GAG with similar structure to HS,33,34 we
simultaneously added FGF-2 and heparin to the cell
culture medium and determined ERK1/2 phosphoryla-
tion in cells of affected individuals. After 10 and 20 min
of treatment, the growth stimulatory effect of FGF-2
was completely restored as the level of ERK1/2 phosphor-
ylation was almost the same in all three cell lines derived
from affected individuals compared to control cells stim-
ulated only with FGF-2 (Figure 6A, compare middle with
lower panel, and Figure 6B). We next added heparin
alone to fibroblasts of affected individuals and measured
ERK1/2 phosphorylation. Similar to the treatment of cells
of affected individuals with FGF-2 alone, addition of
heparin resulted in an increase over baseline of ERK1/2
phosphorylation in these cells; however, the ERK1/2
phosphorylation level was only 1.2- to 1.5-fold and 1.3-
to 1.4-fold higher after 10 min and 20 min, respectively,
of heparin treatment in cells of affected individuals
(Figure S6) (compared to 2.6- to 2.8-fold and 2.3- to 2.5-
fold higher ERK1/2 phosphorylation after 10 min and
20 min, respectively, of FGF-2 stimulation; Figures 6A
and 6B). These results demonstrate that optimal ERK1/212 The American Journal of Human Genetics 107, 1–18, December 3activation in fibroblasts of individuals with bi-allelic
HS2ST1 variants requires both FGF-2 and the GAG
heparin.
Focal Adhesions Concentrate at the Cell Periphery in
Fibroblasts of Individuals with Bi-allelic HS2ST1 Variants
As well as interacting with HPSGs as co-receptors, FGF-2
can additionally interact with other GAGs, such as chon-
droitin sulfate and dermatan sulfate, to activate multiple
signaling pathways.35,36 For example, FGF-2 has been
found to trigger actin cytoskeletal dynamics, such as cell
migration and focal adhesion formation.37–39 Focal adhe-
sion formation requires the local recruitment of focal adhe-
sion proteins, such as focal adhesion kinase, vinculin, and
paxillin.40,41 Interestingly, soluble HS fragments enhance
the formation and activation of focal adhesions,42,43 and
FGF-2 together with 2-O-sulfated chondroitin sulfate
and/or dermatan sulfate affect the formation of focal adhe-
sion complexes, paxillin activation, and cell migration.44
We next examined the effect of FGF-2 stimulation on posi-
tion, number, and length of focal adhesions (FAs) in fibro-
blasts from individuals with bi-allelic HS2ST1 variants and
two controls. Cells were stimulated with FGF-2 and stained
for the FA marker paxillin. In control cells, paxillin ap-
peared as dot-like or elongated structures distributed
throughout the basal surface and at the cell periphery (Fig-
ures 7A and S7), while FAs in cells derived from affected
individuals concentrated at the cell periphery, with fewer
paxillin-positive structures at the basal surface (Figures
7A and S7). We did not observe any difference in the total
amount of paxillin in cell lysates of affected individual-
and control-derived cells (Figure S8). We next classified
FAs as outer and inner FAs (Figure 7B and Subjects and, 2020
Figure 7. Change in Location, but Not Length and Number of Paxillin-Positive Focal Adhesions in Fibroblasts from Affected Individ-
uals
(A) Fibroblasts were seeded on coverslips and incubated with 10 ng/mL FGF-2 for 1 h. Paxillin was stained by mouse anti-paxillin anti-
body followed by anti-mouse Alexa Fluor488-conjugated antibody (green). Nuclear DNA was labeled by DAPI (blue). Cells were imaged
by widefield fluorescence microscopy. Representative images are shown. A magnified view of the boxed region is shown on the right.
Scale bar, 20 mm. Ctrl 1 and 2, control fibroblasts.
(B) Schematic illustration of the categorisation of focal adhesions (FAs) based on distance from the cell membrane (modified according to
Legerstee et al.26). FAs were classified as outer (light green) and inner (dark green) FAs (see Subjects and Methods section for details).
(C) Quantification of inner and outer FAs in FGF-2-treated fibroblasts. The ratio of inner to outer FAs per cell in each experiment was
determined, and the mean ratio of three independent experiments 5 SD is given. One-way ANOVA with Bonferroni correction was
used for statistical analysis: *p % 0.05; **p % 0.01.
(D and E) Quantification of the number and length of FAs in FGF-2-treated fibroblasts. The total number of paxillin-positive FAs (D) and
the FA length (E) of at least 6 cells per cell line and experiment and a minimum of 21 cells in total per cell line from three independent
experiments were determined (see Subjects and Methods for details). The mean number of FAs per cell5 SD (D) and the average length
of FAs 5 SD (E) are illustrated. One-way ANOVA with Bonferroni correction was used for statistical analysis: *p % 0.05; ns, not
significant.
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each cell line. The inner to outer FA ratio was reduced by
1.8- to 2.3-fold in the three cell lines derived from affected
individuals compared to control 1 and 2 cells (Figure 7C).
The average number of FAs per cell and the average length
of FAs were similar in fibroblasts from individuals 1 to 3
and controls (Figures 7D and 7E). These data indicate a
change in the location of paxillin-positive FAs in the three
cell lines of affected individuals compared to control cells.Discussion
Here we demonstrate bi-allelic pathogenic variants in
HS2ST1 to be the underlying genetic cause for a syndromic
phenotype characterized by developmental delay and/or in-
tellectual disability, hypoplastic or absent corpus callosum,
facial dysmorphismwith upslanted palpebral fissures, broad
nasal tip, and wide mouth, skeletal abnormalities, and uni-The Ameor bilateral renal agenesis. Two affected individuals carried
compound heterozygous HS2ST1 variants with a loss-of-
function variant in combination with a missense change.
In the third family, a severely affected fetus and a male
newborn were homozygous for the missense variant
p.Arg189Ser. The three substituted amino acid residues
Asp165, Phe176, and Arg189 are located in or near the bind-
ing cleft for the saccharide substrate of the sulfotransferase
(Figure 2B in Bethea et al.12 and Figure 3 in Liu et al.;45
Figure S9). Structural and mutation analysis of HS2ST1 re-
vealed several amino acid residues to be important for bind-
ing to PAPS and the polysaccharide substrate as well as for
catalytic activity.12,13 Arginine 164 is located next to aspar-
tate 165which is substituted to tyrosine in individual 2. The
HS2ST1 p.Arg164Ala mutant showed a significantly
decreased enzyme activity and abolished binding to 3’-
phosphoadenosine 5’-phosphate (PAP), the product of sul-
fotransferase-catalyzed reactions.13 The p.Asp165Tyr
change may have a similar effect as the p.Arg164Alarican Journal of Human Genetics 107, 1–18, December 3, 2020 13
Please cite this article in press as: Schneeberger et al., Bi-allelic Pathogenic Variants in HS2ST1 Cause a Syndrome Characterized by Devel-
opmental Delay and Corpus Callosum, S..., The American Journal of Human Genetics (2020), https://doi.org/10.1016/j.ajhg.2020.10.007substitution. Arginine 178 is implicated in substrate bind-
ing, and the HS2ST1 mutant p.Arg178Ala showed a signifi-
cant decrease in both enzyme activity and PAP binding.13
Similarly, tyrosine 173 is also in contact with the saccharide
substrate.45 In individual 1, exchange of phenylalanine 176,
located between Tyr173 and Arg178 in the alpha helix 5 re-
gion, by serine may weaken the binding affinity of HS2ST1
to the IdoA and/or GlcA residue and reduce sulfotransferase
activity. In one study, the p.Arg189Ala substitution resulted
in significant loss of HS2ST1 enzyme activity.13 In two other
studies, arginine 189 was found to be important for recogni-
tion of IdoA units and substrate specificity.12,45 Together,
structural and mutational data from HS2ST1 revealed that
the three residues Asp165, Phe176, and Arg189 are located
at structurally and functionally relevant positions, and their
substitution may weaken the binding to HS, redirect the
substrate specificity, and/or reduce the sulfotransferase ac-
tivity.12,13,45
We demonstrate a low and significantly reduced FGF-2-
dependent MAPK signaling response in the three cell lines
of affected individuals that can be restored by exogeneous
heparin.29,30 These data show the importance of 2-O-
sulfated heparin (or HS) for FGF-2-inducedMAPK signaling
in human skin fibroblasts. In a recent study, the degree of
2-O-sulfated cell surface chondroitin and dermatan sulfate
has been shown to modulate FGF-2-induced ERK1/2 acti-
vation, paxillin activation, and cell migration.44 We could
demonstrate that in FGF-2-stimulated fibroblasts of indi-
viduals with bi-allelic pathogenic HS2ST1 variants, the
position of FAs was altered, with a higher density of
paxillin-positive structures at the cell periphery compared
to control cells. The role of cell membrane-bound GAGs
in cytoskeletal organization has previously been demon-
strated.46 For example, an excess of extracellular HS
fragments enhances focal adhesion formation and activa-
tion,42 and 2-O-sulfation of chondroitin and/or dermatan
sulfate is important for mediating cell migration and adhe-
sion.47–49 Together, the data demonstrate that 2-O-sulfated
GAGs play an important role in FGF-2-induced cytoskel-
etal rearrangements; however, more studies are needed to
characterize the multiple potential pathways implicated
in HSPG-dependent actin cytoskeletal dynamics.
Disaccharide analysis of HS from fibroblasts of one in-
dividual with bi-allelic HS2ST1 variants revealed lack of
2-O-sulfation and increase in N- and 6-O-sulfation.
Thus, retention of a normal charge distribution of the
aberrant HS seems to maintain normal FGF-1 and FGF-
2 signaling response in Hs2st1-deficient mouse embry-
onic fibroblasts19 but is unable to achieve the same level
of compensation in human fibroblasts deficient of 2-O-
sulfotransferase 1 activity. In Chinese hamster ovary
cells, the structure and organization of highly sulfated
domains rather than the fine structure of HS were found
to be critical for FGF-2 signaling.32 However, the pheno-
type of Hs2st1-deficient mouse embryos and individuals
with bi-allelic HS2ST1 pathogenic variants indicates
that the aberrantly synthesized HS is not able to14 The American Journal of Human Genetics 107, 1–18, December 3compensate for the lack of 2-O-sulfated HS in a number
of cells and tissues during development (this work and
Merry and Wilson18).
The core phenotype associated with bi-allelic HS2ST1
variants in the four affected individuals comprises develop-
mental delay and/or intellectual disability, corpus cal-
losum hypoplasia or agenesis, facial dysmorphism, flexion
contractures, and broad toes and/or finger tips, especially
of thumbs and halluces. Bilateral renal agenesis was pre-
sent in individual 3 and unilateral renal agenesis in indi-
viduals 2 and 4 (Table 1). Several of the clinical features
observed in the affected individuals were also present in
Hs2st1 knockout mice, although mutant animals were
more severely affected. Hs2st1-deficient mice show
neonatal lethality. All mutant mice have bilateral renal
agenesis,17 suggesting that 2-O-sulfation critically modu-
lates the activity of one or more growth factors involved
in kidney development.19 Indeed, HS modifications by
Hs2st1 have been shown to influence the binding of
growth factors involved in metanephric mesenchyme in-
duction and differentiation in the developing kidney,
while 6-O-sulfated HS is important for growth and branch-
ing of the ureteric bud.50,51 These data suggest that
differentially sulfated HS controls morphogen activity
and function and acts as a switch during the development
of specific organs.50 Hs2st1 knockout mice show abnor-
malities of the skeleton, such as an increase in bone
mineralization, shorter and thicker long bones, and
55% have post-axial polydactyly of one forelimb.17 In
the affected individuals reported here, various skeletal
anomalies have been observed, including flexion contrac-
tures, short hands and feet with brachydactyly, broad
fingertips and toes, clubfoot, supination of feet, kyphosco-
liosis, and delayed bone maturation. None of the four
affected individuals had polydactyly. In chick embryos,
downregulation of HS2ST1 expression resulted in limb
buds that were truncated and reduced in size, while mildly
affected forelimbs showed a defective digit and size reduc-
tion, demonstrating the requirement of HS 2-O-sulfation
for limb development.52 About 40% of the Hs2st1-defi-
cient mice had secondary cleft palate.17 A submucous cleft
palate was also reported in individual 1 (Table 1). Bilateral
iris colobomawas seen in all homozygousHs2st1 knockout
mice and cataract in six of eight mutants.17 Individuals 1
to 3 did not have any ophthalmological anomalies;
however, posterior embryotoxon, iris hypoplasia, and an
anterior polar cataract were observed in individual 4 (Table
1). Two of the four affected individuals had agenesis or
hypoplasia of the corpus callosum. Hs2st1 is expressed in
the developing telencephalon, and Hs2st1/ mouse em-
bryos have severe corpus callosum phenotypes, but with
incomplete penetrance: axons failed to cross the telence-
phalic midline and form knotted bundles.53 More detailed
analysis revealed a repressive function of Hs2st1-modified
HS on Fgf/Erk signaling in the embryonic telencephalic
midline, likely by specific suppression of Fgf17 protein
levels in the corticoseptal boundary.54,55 Thus, the similar, 2020
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deficient of HS2ST1 identify an important role for the 2-
O-sulfotransferase 1 in the developing mammalian telen-
cephalon by tightly controlling MAP kinase signaling. In
summary, data from animal and human studies indicate
the requirement of 2-O-sulfated HS for morphogenesis of
a number of organs during vertebrate development.
Further support for these findings comes from studies of
a knockout mouse for the D-glucuronyl C5-epimerase
(Glce) encoding gene.56 The protein is one of the special-
ized enzymes involved in HS synthesis and catalyzes the
C5-epimerization of GlcA to IdoA, with IdoA being prefer-
entially 2-O-sulfated by HS2ST1.1 Glce-deficient mice show
considerable phenotypic overlap with Hst2st/ mice as
they die after birth, lack kidneys, and show bilateral colo-
bomas and skeletal abnormalities.56 Interestingly, Glce/
embryos lack some phalanges of the fore and hind paws
and often have cleft palate which is reminiscent of short-
ened or missing phalanges of the hand (Figure 3D) and
submucous cleft palate in individual 1 reported here.
Collectively, the data show that HS with 2-O-sulfated
IdoA residues is important for murine kidney, iris, and skel-
etal development.19,56 However, as only pathogenic vari-
ants in HS2ST1 and not GLCE (MIM: 612134) have been
associated with a human Mendelian disorder to date, the
specific requirement of 2-O-sulfated IdoA units for human
development cannot be determined.
In contrast to GLCE and HS2ST1, the HS 6-O-sulfotrans-
ferase 1 (HS6ST1 [MIM: 604846]) is one of three 6-O-sulfo-
transferases which adds sulfate to the C6 ofD-glucosamine
units.1,57 Heterozygous and homozygous missense vari-
ants in HS6ST1 have been shown to contribute, besides
other genetic and/or environmental factors, to normosmic
isolated gonadotropin-releasing hormone deficiency (IGD)
and IGD with an impaired sense of smell (Kallmann syn-
drome; hypogonadotropic hypogonadism 15 with or
without anosmia [MIM: 614880]).58–61 Some clinical fea-
tures of IGD or Kallmann syndrome, such as unilateral
renal agenesis, cryptorchidism, bone abnormalities, and
cleft lip and/or palate (see Balasubramanian and Crowley
in GeneReviews inWeb Resources), can also be found in in-
dividuals with bi-allelic HS2ST1 variants, further support-
ing the idea that correctly O-sulfated HS is an important
modulator of FGF-mediated cell signaling during human
development.
Other disorders linked to genes/proteins involved
in GAG sulfation are CHST3-related skeletal dysplasia
(spondyloepiphyseal dysplasia with congenital joint dislo-
cations [MIM: 143095]), Ehlers-Danlos syndrome, muscu-
locontractural type 1 (EDSMC1 [MIM: 601776]), and
osteochondrodysplasia, brachydactyly, and overlapping
malformed digits (OCBMD [MIM: 618167]).62,63 CHST3-
related skeletal dysplasia is typically characterized by short
stature, joint dislocations, clubfeet, restricted movement,
kyphosis, and minor heart valve dysplasia (see Superti-
Furga and Unger in GeneReviews in Web Resources).
Bi-allelic variants in CHST3 encoding carbohydrate sulfo-The Ametransferase 3 or chondroitin 6-O-sulfotransferase 1 lead to
functional impairment of the enzyme.64,65 EDSMC1 is
caused by bi-allelic pathogenic variants in CHST14 that en-
codes the carbohydrate sulfotransferase 14 (also named
dermatan 4-O-sulfotransferase 1), catalyzing the 4-O-sulfa-
tion of GalNAc residues in dermatan sulfate. Clinically the
syndrome is characterized by craniofacial dysmorphism,
congenital contractures, joint hypermobility, clubfeet, ky-
phoscoliosis, muscular hypotonia, hyperextensible thin
skin, atrial septal defects, and ocular involvement.66–68
OCBMD has been reported in a Pakistani family with a ho-
mozygous in-frame deletion in CHST11 encoding carbohy-
drate sulfotransferase 11 (also named chondroitin 4-O-sul-
fotransferase 1).69 Together, the published and our data
show the importance of the GAG sulfation pathway for
cartilage and bone development.
In conclusion, our data reveal HS2ST1, an enzyme
involved in GAG sulfation, to be associated with a syn-
dromic phenotype comprising neurological, skeletal, and
renal abnormalities. Reduced or absent HS 2-O-sulfotrans-
ferase 1 activity leads to an aberrantly synthesized HS in
cells of affected individuals, with a shift in the global sulfa-
tion pattern. HS2ST1 has to be added to a number of other
sulfotransferases mutated in skeletal dysplasia and connec-
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